Technical Analysis for RCUS - Arcus Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 1.70% | |
| Fell Below 200 DMA | Bearish | 1.70% | |
| Down 3 Days in a Row | Weakness | 1.70% | |
| 20 DMA Resistance | Bearish | 0.24% | |
| NR7 | Range Contraction | 0.24% | |
| Bearish Engulfing | Bearish | -0.77% | |
| Fell Below 20 DMA | Bearish | -0.77% | |
| MACD Bearish Signal Line Cross | Bearish | -0.77% | |
| MACD Bullish Signal Line Cross | Bullish | -6.57% | |
| Pocket Pivot | Bullish Swing Setup | -6.57% |
| Alert | Time |
|---|---|
| Possible NR7 | about 3 hours ago |
| Rose Above Previous Day's High | about 5 hours ago |
| 60 Minute Opening Range Breakout | about 6 hours ago |
| Rose Above 20 DMA | about 6 hours ago |
| 20 DMA Support | about 6 hours ago |
Get a Trading Assistant
- Earnings date: 08/05/2024
Arcus Biosciences, Inc. Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. It is also developing AB154, an anti-T-cell immunoreceptor with Ig and ITIM domains antibody, which is in Phase I trial as monotherapy; and AB680, a small-molecule inhibitor of CD73 that is in Phase I healthy volunteer study. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate AB122, an anti-PD-1 antibody. Arcus Biosciences, Inc. was founded in 2015 and is headquartered in Hayward, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Clinical Development Cancer Treatment Cancer Immunotherapy Monoclonal Antibodies Immunotherapies Adenosine Cd73 Pd 1
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 20.48 |
| 52 Week Low | 12.96 |
| Average Volume | 553,590 |
| 200-Day Moving Average | 16.50 |
| 50-Day Moving Average | 15.93 |
| 20-Day Moving Average | 17.02 |
| 10-Day Moving Average | 16.73 |
| Average True Range | 0.92 |
| RSI (14) | 49.24 |
| ADX | 14.92 |
| +DI | 21.22 |
| -DI | 20.30 |
| Chandelier Exit (Long, 3 ATRs) | 16.00 |
| Chandelier Exit (Short, 3 ATRs) | 18.05 |
| Upper Bollinger Bands | 18.32 |
| Lower Bollinger Band | 15.72 |
| Percent B (%b) | 0.3 |
| BandWidth | 15.30 |
| MACD Line | 0.23 |
| MACD Signal Line | 0.30 |
| MACD Histogram | -0.0704 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.74 | ||||
| Resistance 3 (R3) | 17.86 | 17.56 | 17.53 | ||
| Resistance 2 (R2) | 17.56 | 17.24 | 17.50 | 17.46 | |
| Resistance 1 (R1) | 17.02 | 17.04 | 16.87 | 16.91 | 17.39 |
| Pivot Point | 16.72 | 16.72 | 16.65 | 16.66 | 16.72 |
| Support 1 (S1) | 16.19 | 16.40 | 16.04 | 16.07 | 15.59 |
| Support 2 (S2) | 15.89 | 16.21 | 15.83 | 15.52 | |
| Support 3 (S3) | 15.35 | 15.89 | 15.45 | ||
| Support 4 (S4) | 15.24 |
